Mapi Creates Dedicated Patient Centered Sciences Unit by Combining Patient Centered Outcomes, Patient Insights and Engagement and Direct To Patient Contact Services
Mapi, the leading Patient-Centered Health Research company, today announced the creation of a dedicated unit combining its Patient Centered Outcomes (PCO) team, Patient Insight & Engagement researchers and their Patient Logistics group (PROclinica), the provider of Direct To Patient services, to create transformative integrated solutions across the entire treatment lifecycle for biopharmaceutical clients.
The new dedicated unit, headed by Mapi’s Chief Scientific Officer, Dr. William C Maier, will provide customers with global patient- solutions based on patient perceptions, behaviours and motivations to improve drug efficacy and safety assessment, regulatory and payer acceptance, study design, recruitment and participation in trials, observational studies and pharmaceutical marketing activities.
“Mapi has been the industry innovator and leader in Patient Centered Research longer than most CROs have existed” said Will Maier, Chief Scientific Officer of Mapi. “Through this new business unit we help our clients seamlessly integrate and align Patient Centered Sciences; developing the most complete understanding of patients, their behaviour and preferences, integrating relevant Clinical Outcomes to support endpoints and value based treatment, as well as execute on these combined insights with the industry’s most experienced Direct to Patient Contact experts. Mapi is considered the regulatory and peri- and post-approval research experts, enabling our clients to meet the evidence demands of both regulators and payers for over four decades.”
Experts from the new unit will be presenting at the annual June meeting of the Drug Information Association (DIA) in Chicago.
Benoit Arnould, PhD - Senior Director, Patient-centered Outcomes (PCO), Mapi
- Session Chair & Moderator: Thursday, June 22 at 10:45am - 12:00pm ~ #405: How Do We Retain Patients in Studies? Using the Patients’ Words to Explore Treatment Acceptance and Patient Engagement - Presentation Speaker: Did You Get Why Patients Accept (or Not) Their Long-Term Treatment? Results from an EU study Via Carenity Social Platform
- Session Speaker: Tuesday, June 20 at 2:00pm - 3:15pm ~ #255: Integrating the Patient's Voice Across the Development Program of Rare Diseases: Translation Into Meaningful Outcomes - Presentation: Developing the PKU-QOL: A Long Journey to Integrate the Patients’ Voice into Phenylketonuria Drug Development Programs
Kelly Franchetti, RN, CCRN, CEN - Vice President, Global Patient Insights & Engagement (PI&E), Mapi
- Session Speaker: Wednesday, June 21 at 10:30am ~ #321: Engagement, Education, Networks, Media, and Societies in Rare Diseases: The MUST Haves (Description: Kelly Franchetti) - Presentation: A Mutually Beneficial Partnership: Engaging Advocacy and Patient Groups to Assist with Clinical Trial Recruitment
- Session Speaker: Wednesday, June 21 at 4:00 pm - 5:15 PM ~ #377: Increasing Participation in Clinical Trials Among Under-Represented Populations (Description: Kelly Franchetti) - Presentation: The Inclusive Clinical Trial: Involving Diverse Populations in Clinical Trial Design
Valerie Powell, MS - Director, Global Patient Insights & Engagement (PI&E), Mapi
- Session Speaker: Tuesday, June 20 at 2:00pm - 3:15pm ~ #259: Novel Techniques for Improving Clinical Trial Subject Retention - Presentation: One Size Does Not Fit All: Retention Methods Custom-Designed for Your Specific Patient Population
- Session Speaker: Wednesday, June 21 at 10:30am - 11:45am ~ #315: How to Engage Patients Within Medical Affairs - Presentation: Medical Affairs Engaging Patients for Postmarketing Patient Registry
Will Maier, PhD, MPH - Chief Scientific Officer, Patient-Centered Services, Mapi
- Session speaker: Hybrid Studies Session: Monday, June 19 at 11:00am - 12:15pm ~ #125: Hybrid Study Designs: An Innovate Approach to Obtaining Valuable Information by Combining Existing Data with New Data Length - Presentation: Why Choosing a Hybrid Design? Insights from a Study with Duchenne Muscular Dystrophy Patients and Caregivers
Margaret Richards, PhD, MPH - Vice President, Data Analytics and Epidemiology, Real World Strategy and Analytics (RWS&A), Mapi
- Session Panelist: Sunday, June 18 at 2:45 pm - 4:00 pm ~ #001: To Change or Not to Change, That is the Career Question: Knowing When it’s Time to Move On (Not, Run From)
- Session Chair: Monday, June 19 at 11:00 am - 12:15 pm ~ #125: Hybrid Study Designs: An Innovative Approach to Obtaining Valuable Information by Combining Existing Data with New Data Length
- Session Chair: Wednesday, June 21 at 9:30 am - 10:30 am ~ #304: Mergers and Acquisitions: First, Do No Harm